Castle Biosciences (CSTL) Stock Forecast — 2-Week Outlook

StockMap's current 2-week read on Castle Biosciences (CSTL) is Neutral.

The composite score behind that read is +0.08, weighing +0.17 of bullish evidence against -0.21 bearish.

Castle Biosciences last closed at $34.42, +2.11% on the session.

Against the IVW growth benchmark the position is +1.31% over the forecast window.

The read is built from 15 underlying insights — 4 bullish and 11 bearish.

Agreement across those insights is 73%.

10 graded predictions for CSTL so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.

On the fundamentals StockMap ranks Castle Biosciences in the 36th percentile on return on equity, where 100 is best.

Castle Biosciences is classified under Health Care / Health Care Providers & Services, with a market capitalisation of $1.03B.

StockMap tracks Castle Biosciences as the 57th largest of the 85 companies it covers in the Health Care Providers & Services industry, part of the Health Care sector.

Across that group the current two-week reads are 81 Neutral and 4 Moderate Underperform.

On that composite Castle Biosciences ranks 13th of 85 in the group, against a group median of +0.00.